Pfizer, like some other big drug makers, is facing tepid growth amid generic competition and the lack of clear blockbusters in its drug pipeline. 和其它大型制药企业一样，辉瑞也面临着因普通药物的竞争而导致的业务增长缓慢，同时它研制的药物中尚缺乏能带来巨大效益的轰动性药物。
The research progress on applications of MIP in chiral drug separation and clinical drug analysis in the recent years was expounded. 综述了近年来分子印迹聚合物在手性药物分离和临床药物分析应用方面的研究进展。
